Our Keynote colorectal cancer clinical trials are studying pembrolizumab to see if it may help patients with colorectal cancers. Pembrolizumab is an investigational immunotherapy that targets the PD-1 pathway.
Pembrolizumab has been FDA-approved for use in certain types of cancer.
Microsatellite instability (MSI) in patients with colorectal cancer
In most people, proteins known as MMR (mismatch repair) correct errors in the DNA when it is copied in a cell. However, in some patients with colorectal cancers, the genes that form the MMR proteins contain mutations. This leads to failure of the DNA repair mechanism to correct errors in nucleotide repeat markers, which is known as a deficient MMR (dMMR) system. Tumors that have a dMMR system can develop microsatellite instability (MSI). If the instability occurs in more than 30% of DNA parts examined, the cancer cells are considered to be microsatellite instability-H (MSI-H).1,2
If you have patients with untreated, stage IV MSI-H or dMMR metastatic colorectal cancer, consider the Keynote 177 clinical trial.
Clinical trials for colorectal cancer are underway and currently enrolling patients. To see if your patients qualify for one of these trials, contact our clinical trial information center at 1-888-577-8839. If you are interested in partnering with us as an investigator, call 1-800-290-4339.
|Trial Description||Keynote Trial||Condition||Phase||Status|
|Study of Pembrolizumab as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer||164||Colorectal Carcinoma||Phase 2||Active, not recruiting|
|Study of Pembrolizumab vs Standard Therapy in Participants With Microsatellite Instability-High or Mismatch Repair Deficient Stage IV Colorectal Carcinoma||177||Colorectal Carcinoma||Phase 3||Active, not recruiting|